Management of Serotonin Syndrome and Neuroleptic Malignant Syndrome
Tóm tắt
Serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS) can present similarly and range in severity from mild to life-threatening. Although they are easily misdiagnosed, each is distinct clinically and pathophysiologically. It is important to distinguish between the two, as therapeutic options differ. An accurate and thorough medication history plus knowledge of the various clinical presentations of both syndromes are the first steps in management. After this, removing the offending agents and aggressive supportive care are crucial. This includes controlling muscle rigidity and hyperthermia, providing cardiovascular support, and alleviating agitation. In severe cases, paralysis, sedation, and intubation are required. Agents to reverse either surplus serotonergic activity or dopamine blockage can be useful. However, the diagnosis must be clear, as use of these agents in the incorrect syndrome can worsen symptoms. In pharmacologically refractory cases of NMS, electroconvulsive therapy should be pursued.
Tài liệu tham khảo
Sternback H. The serotonin syndrome. Am J Psychiatry. 1991;148:705–13.
Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112–20. A comprehensive review of serotonin syndrome.
Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry. 2012;24(2):155–62.
Dosi R et al. Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary. BMJ Case Rep 2014.
Bienvenu OJ, Neufeld KJ, Needham DM. Treatment of four psychiatric emergencies in the intensive care unit. Crit Care Med. 2012;40:2662–70. A concise review of syndrome features and specific treatment recommendations.
Langan J et al. Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome: literature review and case series report. BMC Psychiatry. 2012;12:214.
Newman EJ, Grosset DG, Kennedy PGE. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10:136–40.
Frucht S. Treatment of movement disorder emergencies. Neurotherapeutics. 2014;11:208–12.
Musselman ME, Suprat S. Diagnosis and treatment of drug-induced hyperthermia. Am J Health-Syst Pharm. 2013;70:34–42.
Product information Dantrium (Dantrolene sodium). Pfizer Australia Pty Ltd. 2010.
Davies O et al. Full recovery after severe serotonin syndrome, severe rhabomyolysis, multi-organ failure and disseminated intravascular coagulopathy from MDMA. Heart Lung. 2014;43:117–9.
Product information periactin (cyproheptadine hydrochloride). Aspen Pharmacare Australia Pty Ltd. 2011.
Product monograph teva-chlorpromazine. Teva Canada Limited. 2012.
Prescribing information for Zyprexa (Olanzepine): Eli Lilly and Company. 2014.
Prescribing information for Parlodel (Bromocriptine mesylate). Validus Pharmaceuticals LLC. 2014.
Luchini F et al. Electroconvulsive therapy in catatonic patients: efficacy and predictors of response. World J Psychiatry. 2015;5(2):182–92.
Cheng YC et al. Serotonin Syndrome after electroconvulsive therapy in a patient on trazodone, bupropion, and quetiapine: a case report. Clin Neuropharm. 2015;38:112–3.
Klysner R et al. Transient serotonin toxicity evoked by combination of electroconvulsive therapy and fluoxetine. Case Rep Psychiatry. 2014: 162502.